Tolerance Study of the Silicone Bands on Medical Compression Stockings

Inclusion Criteria: * Subjects who notified a health care professional (doctor or pharmacist) of an incident with a grip-top bands compression stocking, regardless of brand and model. * Subjects presenting skin lesions caused by the contact with silicone-containing grip-top bands of medical compression stockings (all brands combined). * Subjects for whom the incriminated stockings provide class 2 compression or higher. * Subjects covered by French national health insurance. * Subjects who give their written informed consent and who accept the constraints of the study. Exclusion Criteria: * Known allergy to local anesthetics (lidocaine, etc.). * History of anaphylactic shock. * Ongoing antihistamine treatment or having taken during the week before inclusion. * Patient on ongoing systemic corticosteroids or having taken corticosteroids in the month before inclusion. * Patient having used a topical corticosteroid in the area where the patch tests or prick tests will be performed during the week before inclusion. * Phototherapy or sun exposure in the 30 days preceding the skin tests (on the back). * Patient having concomitantly used compression stockings and a topical corticosteroid on the thighs in the 48 hours preceding lesion onset. * List of diseases which will prevent a subject from participating in the study: * acquired, infectious or drug-induced congenital immunosuppression (systemic corticosteroid therapy, immunosuppressives, chemotherapy), * Congenital bullous disorder (congenital epidermolysis bullosa) or acquired bullous disorder (pemphigus, pemphigoid, dermatitis herpetiformis, linear IgA dermatosis, etc.). * Patients with an ongoing or previous history of mental or psychiatric disorder or condition or any other factor interfering with the ability to give informed consent. * Any major systemic disease making the conduct of the study or the interpretation of the results difficult. * Patients with ongoing or previous history of decompensated heart failure. * Chemotherapy or active cancer. * Pregnancy. * Patients participating in an ongoing clinical trial or in the exclusion period of a previous trial. * Persons deprived of their liberty by judicial or administrative decision or persons hospitalized without their consent. * Legally protected adults under guardianship. * If the patient accepts the biopsy proposed in the study: * Patient for whom a skin biopsy is contra-indicated or requiring antibiotic prophylaxis, * Anticoagulant taken during the 24 hours before inclusion. * Subject with history of allergy to natural or synthetic latex, chlorhexidine, known healing disorder and/or viral diseases transmissible through the blood documented by the preliminary clinical exam.